Try a new search

Format these results:

Searched for:

in-biosketch:true

person:rosesd01

Total Results:

278


Assessment of hormone receptor status and HER2 expression by fine needle aspiration biopsy in breast cancer [Meeting Abstract]

Hussain, M; Cangiarella, J; Volm, M; Harris, MN; Roses, DF; Berman, RS
ISI:000184429300148
ISSN: 1068-9265
CID: 38553

Hypo-Fractionated Conformal Radiation Therapy to the Tumor Bed After Segmental Mastectomy

Formenti, Silvia C; Roses, Daniel; Harris, Matthew; Shapiro, Richard; Guth, Amber
[Ft. Belvoir, VA] : Ft. Belvoir Defense Technical Information Center, 2003
Extent: 20 p.
ISBN: n/a
CID: 2130

Prognostic significance of the high molecular weight-melanoma associated antigen in sera of patients with melanoma [Meeting Abstract]

Wainwright, BD; Reynolds, SR; Ferrone, S; Harris, RL; Harris, MN; Roses, DF; Bystryn, J
ISI:000177428100209
ISSN: 0022-202x
CID: 55285

Presence of Mab 465.12 defined cytoplasmic melanoma-associated antigen in sera of patients with melanoma and relation to prognosis [Meeting Abstract]

Levy, D; Reynolds, SR; Ferrone, S; Shapiro, RL; Harris, MN; Roses, DF; Bystryn, J
ISI:000177428100198
ISSN: 0022-202x
CID: 55283

Long-term survival of stage IV melanoma patients treated with a polyvalent, shed antigen, melanoma vaccine [Meeting Abstract]

Laky, D; Shapiro, RL; Harris, MN; Roses, DF; Jacquotte, AZ; Reynolds, SR; Bystryn, J
ISI:000177428100199
ISSN: 0022-202x
CID: 55284

Management or regional lymph nodes in patients with cutanesou melanoma

Chapter by: Roses DF
in: Surgical oncology : multidisciplinary approach to difficult problems by Silberman AW; Silberman J [Eds]
New York : Arnold, 2002
pp. 416-443
ISBN: 034076242x
CID: 2768

Hypo-Fractionated Conformal Radiation Therapy to the Tumor Bed After Segmental Mastectomy

Formenti, Silvia C; Roses, Daniel; Harris, Matthew; Shapiro, Richard; Guth, Amber
[Ft. Belvoir, VA] : Ft. Belvoir Defense Technical Information Center, 2002
Extent: 53 p.
ISBN: n/a
CID: 2129

Elective radiation therapy for high-risk malignant melanomas

Cooper JS; Chang WS; Oratz R; Shapiro RL; Roses DF
PURPOSE: Local-regional recurrence rates of 30%-50% have been reported after resection of high-risk malignant melanomas (multiple node involvement, extracapsular spread, deep invasion, recurrent disease, and/or microscopically involved margins). Recently, we have been offering elective radiation therapy, after definitive surgery, to selected patients who have high-risk malignant melanomas. We herein report our initial results. PATIENTS AND METHODS: From 1993 to 1999, 40 patients who underwent surgery for high-risk malignant melanomas (multiple involved lymph nodes [21 patients]; close or microscopically involved surgical margins [nine patients]; extracapsular extension [six patients]; previously resected, recurrent disease [three patients]; and/or primary tumors more than 4 mm thick [four patients]) received elective radiation therapy. Thirty-six patients received 3000 cGy in five fractions (600 cGy per fraction given twice weekly), and four patients received 3600 cGy in six fractions. RESULTS: At a median follow-up of 18.4 months (range, 3.8-74.1 months), the actuarial 5-year local-regional control rate was 84%. Systemic recurrence rates in these patients were similar to those reported for this subset of patients, and the actuarial overall survival rate at 5 years was 39%. Acute toxicity was limited to erythema of the skin and, in one instance, probable cellulitis, with no late sequelae. DISCUSSION: Elective radiation therapy (600 cGy per fraction for five or six fractions) effectively controlled residual subclinical disease after surgery; however, better adjuvant systemic therapies need to be designed to eliminate distant metastases and to alter survival rates
PMID: 11769862
ISSN: 1528-9117
CID: 25143

Decreases in serum levels of S100 may predict response to therapy in melanoma patients treated with a polyvalent melanoma vaccine [Meeting Abstract]

Bar, A; Amin, P; Reynolds, S; Shapiro, R; Roses, D; Harris, M; Bystryn, J
ISI:000170668300931
ISSN: 0022-202x
CID: 54910

Serum S100 level is predictive of recurrence-free survival in patients with intermediate risk melanoma [Meeting Abstract]

Amin, P; Bar, A; Reynolds, S; Shapiro, R; Harris, M; Roses, D; Bystryn, J
ISI:000170668300500
ISSN: 0022-202x
CID: 54900